Comments regarding ‘Predictive Risk Factors for Restenosis after Remote Superficial Femoral Artery Endarterectomy’  by Schneider, J.R.
Eur J Vasc Endovasc Surg (2010) 39, 604e605INVITED COMMENTARY
Comments regarding ‘Predictive Risk Factors for
Restenosis after Remote Superficial Femoral
Artery Endarterectomy’J.R. Schneider*Vascular and Interventional Program of Central DuPage Hospital, 25 North Winfield Road, Northwestern University,
Winfield, IL 60190, USA
Submitted 3 March 2010; accepted 3 March 2010
Available online 25 March 2010Dr. Derksen and colleagues have presented an interesting
analysis from the large experience with RSFAE in the
Netherlands. Eighty percent of subjects were claudicants.
Indication for operation was not an independent predictor of
primary patency as was the case in their previous publica-
tion1 discrepant from results of bypass, which are clearly
better in claudicants than in critical limb ischemia.
Furthermore, it appears that 14 subjects returned with
critical ischemia, presumably with thrombosis of the previ-
ously treated SFA. Presumably some of these patients were
initially treated for claudication and were, therefore,
‘‘worse’’ when the SFA thrombosed. This is generally not
observed early after bypass, i.e., claudicants generally
revert to claudication, not critical ischemia when a femo-
ropopliteal bypass fails early. This observation suggests that
one should likely be more reluctant to recommend RSFAE in
claudicants, at least in those with smaller arteries or longer
period of symptoms based on the results of the current study.
More than half of the subjects suffered stenosis of 50% or
worse and secondary patency was 61% at one year, similar
to the authors’ results in a randomized trial (REVAS)1 of
RSFAE vs. prosthetic bypass. This is certainly lower than one
expects in modern series of femoropopliteal bypass evenDOI of original article: 10.1016/j.ejves.2010.01.015.
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doi:10.1016/j.ejvs.2010.03.002with prosthetic grafts. For example, in a recent randomized
comparison of ePTFE femoropopliteal bypass and Viabahn
stent grafting2 the secondary patency of prosthetic bypass
was 84% at one year in a group with about 70% claudicants.
However, despite randomization in REVAS, the bypass group
had more diseased outflow. Patency is dependent on
outflow and other patient characteristics and thus, it is
possible that this affected results. A larger study might
show that bypass even with prosthetic material still
provides better patency than RSFAE.
There is no immediately apparent explanation for the
observation that patency is worse as age increases and this
is contrary to the observations with bypass where patency
actually seems better in older patients. This is clearly the
largest published experience in RSFAE and we will all be
anxious to see whether this observation is reproduced by
others. The observation that vessel diameter is predictive
of results is certainly consistent with our approach, i.e., we
are reluctant to use RSFAE (or prosthetic bypass) when the
distal reconstituted popliteal artery is small. The observa-
tion that duration of symptoms was associated with poorer
patency after RSFAE is to my knowledge unprecedented in
the literature of bypass. The proposed explanation,
essentially that the SFA may shrink over time when
occluded, is plausible. As the authors’ dataset increases in
number of subjects and others adopt and report results
with RSFAE, such an explanation would be supported if
multivariate analysis showed duration of symptoms to be and by Elsevier Ltd. All rights reserved.
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diameter. However, this would, as the authors suggest,
imply that bypass should be favored as duration of symp-
toms increases.
RSFAE has an important role in patients with symp-
tomatic SFA disease. I congratulate the authors on their
review of ‘‘all comers’’ of the largest experience with
RSFAE and the guidance that their observations provide
for patient selection. We continue to recommend vein
bypass for patients with TASC C and D disease of the SFA
and clear indications for intervention3 and the authors
appear to subscribe to this view as well, but we must
consider endovascular treatment,4 prosthetic bypass, and
RSFAE for such patients. As is always the case, choosing
the right intervention (if any) for the patient provides
superior results. The authors have provided intriguing
evidence that in the absence of autologous vein conduit
for bypass, younger patients with shorter duration of
symptoms and larger arteries should be strongly consid-
ered for RSFAE.References
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